Results 21 to 30 of about 65,110 (152)

Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists

Endocrinology Research and Practice, 2022
Glucagon-like peptide-1 is the most potent incretin secreted from the intestinal tract. It is synthesized by L-cells in the jejunum and distal ileum of the gastrointestinal system.
Dilek Tüzün
doaj  

Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation

Neural Regeneration Research, 2020
Glucagon-like peptide-1 receptor has anti-apoptotic, anti-inflammatory, and neuroprotective effects. It is now recognized that the occurrence and development of chronic pain are strongly associated with anti-inflammatory responses; however, it is not ...
Shan-Shan Cui, Xiao-Bo Feng, Bing-Hong Zhang, Zhong-Yuan Xia, Li-Ying Zhan   +4 more
doaj   +1 more source

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]

Electronic Physician, 2013
:Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes.Methods: This was a quasi-experimental study. The population was consisted
Roja Daliri, Sara Heidarzadeh, Parvin Farzanegi, Mohammad Ali Azarbayjani   +3 more
doaj   +3 more sources

GLP1R rs3765467 Polymorphism Is Associated with the Risk of Early Onset Type 2 Diabetes

International Journal of Endocrinology, 2023
Objective. To investigate the relationship between glucagon-like peptide-1 receptor gene polymorphisms and susceptibility to early onset type 2 diabetes. Methods.
Yunyun Fang, Jingjing Zhang, Linlin Ji, Chaoyu Zhu, Yuanyuan Xiao, Qingge Gao, Wenjing Song, Li Wei   +7 more
doaj   +1 more source

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

PLoS ONE, 2015
AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts, Laura J Gray, Emer M Brady, Kamlesh Khunti, Melanie J Davies, Danielle H Bodicoat   +5 more
doaj   +1 more source

EVIDENCE OF THE INFLUENCE OF GLUCAGON-LIKE PEPTIDE ANALOGS IN INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW [PDF]

Arquivos de Gastroenterologia
Background: Inflammatory bowel disease is a chronic, immune-mediated condition characterized by relapsing intestinal inflammation and progressive tissue damage.
Lucas Dalvi Armond REZENDE, Camila ADOUR, Gabriel Confalonieri BERTOLDI, Marco Antônio Oliveira BRITO, Flávia Lúcia CONCEIÇÃO, Mariana Poltronieri PACHECO   +5 more
doaj   +2 more sources

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Journal of Diabetes Investigation, 2022
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study.
Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group   +8 more
doaj   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice
Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review ...
Nour Ghostine, Maya Halabi‐Tawil
doaj   +1 more source

Topical administration of GLP-1 eyedrops improves retinal ganglion cell function by facilitating presynaptic GABA release in early experimental diabetes

Neural Regeneration Research
Diabetic retinopathy is a prominent cause of blindness in adults, with early retinal ganglion cell loss contributing to visual dysfunction or blindness.
Yu-Qi Shao, Yong-Chen Wang, Lu Wang, Hang-Ze Ruan, Yun-Feng Liu, Ti-Hui Zhang, Shi-Jun Weng, Xiong-Li Yang, Yong-Mei Zhong   +8 more
doaj   +1 more source

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

Journal of Diabetes
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci   +2 more
doaj   +1 more source